Literature DB >> 17062028

Treatment of inflammatory dermatoses by tumour necrosis factor antagonists.

A Jacobi1, V Mahler, G Schuler, M Hertl.   

Abstract

BACKGROUND: The treatment of inflammatory skin diseases is at present often empirical as causal therapeutic approaches, based on an incomplete knowledge of the immune pathogenesis, are mostly unavailable. The currently applied treatments can in fact lead to remission of the disease; however, under certain circumstances undesirable side-effects must be expected. On the basis of experience gained in cytokine modulation therapy of chronic inflammatory diseases such as rheumatoid arthritis and psoriasis, the application of TNF-alpha inhibitors represents a novel, more specific, and effective therapeutic option for distinct chronic inflammatory diseases. PATIENTS AND METHODS: The current status of the therapeutic effect of TNF-alpha blockers is discussed based on our own observations and a review of the current literature. Also discussed are potential undesirable side-effects and possible contraindications of this therapy. RESULTS AND
CONCLUSIONS: Based on recent findings, the use of TNF-alpha blockers seems to be promising in the treatment of therapy-resistant inflammatory dermatoses. At present, guidelines for indications and contraindications of anti-TNF-alpha treatment of inflammatory skin disorders are rare. Such guidelines are necessary to improve the efficacy of anticytokine treatment and the reduction of side-effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17062028     DOI: 10.1111/j.1468-3083.2006.01733.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  3 in total

1.  Bioactive Bibenzyl Enantiomers From the Tubers of Bletilla striata.

Authors:  Mei Zhou; Sai Jiang; Changfen Chen; Jinyu Li; Huayong Lou; Mengyun Wang; Gezhou Liu; Hanfei Liu; Ting Liu; Weidong Pan
Journal:  Front Chem       Date:  2022-06-09       Impact factor: 5.545

2.  Design, Synthesis, and Evaluation of Dihydrobenzo[cd]indole-6-sulfonamide as TNF-α Inhibitors.

Authors:  Xiaobing Deng; Xiaoling Zhang; Bo Tang; Hongbo Liu; Qi Shen; Ying Liu; Luhua Lai
Journal:  Front Chem       Date:  2018-04-04       Impact factor: 5.221

3.  Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases.

Authors:  Siba P Raychaudhuri; Smriti K Raychaudhuri
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.